Double‐blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase‐4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT‐I Study

Ronan Roussel; Santiago Duran‐García; Yilong Zhang; Suneri Shah; Carolyn Darmiento; R. Ravi Shankar; Gregory T. Golm; Raymond L. H. Lam; Edward A. O'Neill; Ira Gantz; Keith D. Kaufman; Samuel S. Engel

doi:10.1111/dom.13574

Double‐blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase‐4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT‐I Study

Diabetes Obesity and Metabolism ◽

10.1111/dom.13574 ◽

2019 ◽

Vol 21 (4) ◽

pp. 781-790 ◽

Cited By ~ 8

Author(s):

Ronan Roussel ◽

Santiago Duran‐García ◽

Yilong Zhang ◽

Suneri Shah ◽

Carolyn Darmiento ◽

...

Keyword(s):

Type 2 Diabetes ◽

Clinical Trial ◽

Insulin Glargine ◽

Randomized Clinical Trial ◽

Dipeptidyl Peptidase ◽

Efficacy And Safety ◽

Double Blind ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy

Current Medical Research and Opinion ◽

10.1080/03007995.2017.1335637 ◽

2017 ◽

Vol 33 (10) ◽

pp. 1853-1860 ◽

Cited By ~ 7

Author(s):

R. Ravi Shankar ◽

Silvio E. Inzucchi ◽

Victoria Scarabello ◽

Ira Gantz ◽

Keith D. Kaufman ◽

...

Keyword(s):

Type 2 Diabetes ◽

Clinical Trial ◽

Randomized Clinical Trial ◽

Dipeptidyl Peptidase ◽

Efficacy And Safety ◽

Dipeptidyl Peptidase 4 ◽

Metformin Monotherapy ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes

Diabetes Research and Clinical Practice ◽

10.1016/j.diabres.2017.10.018 ◽

2018 ◽

Vol 138 ◽

pp. 253-261 ◽

Cited By ~ 8

Author(s):

Philip Home ◽

R. Ravi Shankar ◽

Ira Gantz ◽

Carol Iredale ◽

Edward A. O'Neill ◽

...

Keyword(s):

Type 2 Diabetes ◽

Dipeptidyl Peptidase ◽

Double Blind Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Dipeptidyl Peptidase 4 ◽

Blind Trial ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

Current Medical Research and Opinion ◽

10.1185/03007990903156111 ◽

2009 ◽

Vol 25 (10) ◽

pp. 2361-2371 ◽

Cited By ~ 97

Author(s):

Richard E. Pratley ◽

Jane E.-B. Reusch ◽

Penny R. Fleck ◽

Craig A. Wilson ◽

Qais Mekki ◽

...

Keyword(s):

Type 2 Diabetes ◽

Dipeptidyl Peptidase ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Treatment With the Dipeptidyl Peptidase-4 Inhibitor Linagliptin or Placebo Followed by Glimepiride in Patients With Type 2 Diabetes With Moderate to Severe Renal Impairment: A 52-Week, Randomized, Double-Blind Clinical Trial: Figure 1

Diabetes Care ◽

10.2337/dc14-1684 ◽

2015 ◽

Vol 38 (2) ◽

pp. e15-e17 ◽

Cited By ~ 27

Author(s):

Markku Laakso ◽

Julio Rosenstock ◽

Per-Henrik Groop ◽

Anthony H. Barnett ◽

Baptist Gallwitz ◽

...

Keyword(s):

Type 2 Diabetes ◽

Clinical Trial ◽

Renal Impairment ◽

Severe Renal Impairment ◽

Dipeptidyl Peptidase ◽

Double Blind ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Double Blind Clinical Trial

Download Full-text

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

Clinical Therapeutics ◽

10.1016/j.clinthera.2006.10.007 ◽

2006 ◽

Vol 28 (10) ◽

pp. 1556-1568 ◽

Cited By ~ 354

Author(s):

Julio Rosenstock ◽

Ronald Brazg ◽

Paula J. Andryuk ◽

Kaifeng Lu ◽

Peter Stein

Keyword(s):

Type 2 Diabetes ◽

Dipeptidyl Peptidase ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Parallel Group Study ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Parallel Group

Download Full-text

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial

Diabetes Obesity and Metabolism ◽

10.1111/j.1463-1326.2006.00704.x ◽

2007 ◽

Vol 9 (2) ◽

pp. 194-205 ◽

Cited By ~ 432

Author(s):

M. A. Nauck ◽

G. Meininger ◽

D. Sheng ◽

L. Terranella ◽

P. P. Stein ◽

...

Keyword(s):

Type 2 Diabetes ◽

Dipeptidyl Peptidase ◽

Efficacy And Safety ◽

Double Blind ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on m

Diabetes Obesity and Metabolism ◽

10.1111/dom.12832 ◽

2017 ◽

Vol 19 (3) ◽

pp. 394-400 ◽

Cited By ~ 14

Author(s):

Ronald Goldenberg ◽

Ira Gantz ◽

Paula J. Andryuk ◽

Edward A. O'Neill ◽

Keith D. Kaufman ◽

...

Keyword(s):

Type 2 Diabetes ◽

Clinical Trial ◽

Randomized Clinical Trial ◽

Dipeptidyl Peptidase ◽

Efficacy And Safety ◽

Once Daily ◽

Dipeptidyl Peptidase 4

Download Full-text

Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12631 ◽

2016 ◽

Vol 18 (5) ◽

pp. 528-532 ◽

Cited By ~ 12

Author(s):

S. Hong ◽

C.-Y. Park ◽

K. A. Han ◽

C. H. Chung ◽

B. J. Ku ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

Diabetes Obesity and Metabolism ◽

10.1111/j.1463-1326.2008.01016.x ◽

2009 ◽

Vol 11 (2) ◽

pp. 167-176 ◽

Cited By ~ 114

Author(s):

R. E. Pratley ◽

M. S. Kipnes ◽

P. R. Fleck ◽

C. Wilson ◽

Q. Mekki ◽

...

Keyword(s):

Type 2 Diabetes ◽

Dipeptidyl Peptidase ◽

Efficacy And Safety ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Efficacy and safety of the addition of a dipeptidyl peptidase-4 inhibitor to insulin therapy in patients with type 2 diabetes: A systematic review and meta-analysis

Diabetes Research and Clinical Practice ◽

10.1016/j.diabres.2016.03.011 ◽

2016 ◽

Vol 116 ◽

pp. 86-95 ◽

Cited By ~ 16

Author(s):

Yeong Gi Kim ◽

Se Hee Min ◽

Seokyung Hahn ◽

Tae Jung Oh ◽

Kyong Soo Park ◽

...

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Insulin Therapy ◽

Meta Analysis ◽

Dipeptidyl Peptidase ◽

Efficacy And Safety ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text